{"id":134117,"date":"2024-09-23T09:45:16","date_gmt":"2024-09-23T04:15:16","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=134117"},"modified":"2024-09-23T09:45:20","modified_gmt":"2024-09-23T04:15:20","slug":"fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/","title":{"rendered":"Fundamentally strong pharma stocks to buy now for an upside of 30%"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-1029015640\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>The Indian pharmaceutical industry is expected to double in value by 2030, presenting an attractive opportunity for long-term investment. Pharmaceutical stocks are appealing due to the sector&#8217;s resilience against market fluctuations and robust growth potential, fueled by rising healthcare demands and government support for innovation. Investors may find significant prospects in this evolving market landscape.&nbsp;<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-680046521\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p><strong>Here are a few pharmaceutical stocks recommended by analysts with high-growth potential of up to 27 percent:&nbsp;<\/strong><\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong><a href=\"https:\/\/portal.tradebrains.in\/stock\/MANKIND\/consolidated\" target=\"_blank\" rel=\"noreferrer noopener\">Mankind Pharma Limited<\/a><\/strong><\/h2><p>With a market capitalization of Rs.1 lakh crore, the share price of Mankind Pharma Limited reached an intra-day high of Rs.2,645 per share on Monday, rising 3.8 percent from its previous close.&nbsp;<\/p><p>Investec, a prominent brokerage firm, has recommended a \u201cBuy\u201d call on Mankind Pharma Limited with a <strong>target price of Rs.3,300 per share, indicating an upside potential of 25 percent.&nbsp;<\/strong><\/p><div class=\"trade-content_5\" id=\"trade-460480743\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>The brokerage noted that Mankind Pharma&#8217;s innovation-driven goal aligns well with Bharat Serums and Vaccines (BSV).&nbsp;<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Also Read: <a href=\"https:\/\/tradebrains.in\/features\/itc-stock-revenue-split-of-itc-from-each-of-its-products\/\" target=\"_blank\" rel=\"noreferrer noopener\">ITC Stock: Revenue split of ITC from each of its products<\/a><\/strong><\/p><\/blockquote><p>The brokerage believes the market underestimates BSV&#8217;s unique advantages, projecting potential sales of $1 billion and over 35 percent EBITDAM (Earnings Before Interest, Taxes, Depreciation, Amortization, and Management Fees.) by FY32 under Mankind&#8217;s management, representing a significant improvement of over 1,000 basis points.&nbsp;<\/p><p>Investec sees BSV&#8217;s specialty strengths in R&amp;D and sourcing as valuable assets that can enhance Mankind&#8217;s vision and drive long-term growth. BSV&#8217;s strong presence in India is expected to boost sales, particularly in the largely untapped $6 billion IVF market.&nbsp;<\/p><p>In its recent financial updates, Mankind Pharma reported revenue of Rs.2,403 crore in Q1FY25, marking a 15 percent growth from Rs.2,092 crore in Q1FY24. Similarly, the company&#8217;s net profit grew to Rs.513 crore from Rs.409 crore in the same period, reflecting a 25 percent increase.&nbsp;<\/p><p>In terms of return ratios, return on capital employed (ROCE) is currently at 24.6 percent, while return on equity (ROE) is at 19.7 percent. The company has a strong current ratio of 2.04 and a low debt-to-equity ratio of 0.0.&nbsp;<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong><a href=\"https:\/\/portal.tradebrains.in\/stock\/YATHARTH\/standalone\" target=\"_blank\" rel=\"noreferrer noopener\">Yatharth Hospital &amp; Trauma Care Services Limited<\/a><\/strong><\/h2><p>With a market capitalization of Rs.4,808 crore, the share price of Yatharth Hospital &amp; Trauma Care Services Limited reached an intra-day high of Rs.584.95 per share on Monday, rising 4.4 percent from its previous close.<\/p><div class=\"trade-content-10\" id=\"trade-475867946\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_3_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"2969612066\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>Edelweiss, a renowned brokerage and wealth management firm, has recommended a \u201cBuy\u201d rating on Yatharth Hospital &amp; Trauma Care Services Limited with a <strong>target price of Rs.740 per share, indicating an upside potential of 27 percent <\/strong>from the current market price.&nbsp;<\/p><p>The brokerage believes Yatharth Hospital aims to double its bed count within three years by strategically acquiring new beds. This expansion is expected to boost capacity and services to accommodate a growing patient base.&nbsp;<\/p><p>Yatharth Hospital aims to increase its share of international patients by tapping into the lucrative medical tourism market, potentially boosting profitability significantly.&nbsp;<\/p><p>In its recent financial updates, the company reported revenue of Rs.212 crore in Q1FY25, marking a 37 percent growth from Rs.155 crore in Q1FY24. Similarly, the net profit of the company grew to Rs.30 crore from Rs.19 crore in the same period, reflecting a 58 percent increase.&nbsp;<\/p><p>In terms of return ratios, return on capital employed (ROCE) stands at 23.6 percent, while return on equity (ROE) is at 21.7 percent. The company also features a strong current ratio of 7.59 and a low debt-to-equity ratio of 0.10.&nbsp;<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Also Read: <a href=\"https:\/\/tradebrains.in\/features\/smallcap-stock-jumps-4-after-company-to-supply-subsystems-for-unmanned-aircraft-vehicles\/\" target=\"_blank\" rel=\"noreferrer noopener\">Smallcap stock jumps 4% after company to supply subsystems\u00a0for unmanned aircraft vehicles<\/a><\/strong><\/p><\/blockquote><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by &#8211; Siddesh S Raskar\u00a0<\/strong><\/p><\/blockquote><h4 class=\"wp-block-heading has-medium-font-size\" id=\"h-disclaimer\"><strong>Disclaimer<\/strong><\/h4><div class=\"wp-block-image\"><figure class=\"aligncenter size-medium\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer-300x300.png\" alt=\"\" class=\"wp-image-26306\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on <a href=\"http:\/\/tradebrains.in\/\">tradebrains.in<\/a> are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing<\/strong>.<\/p><div class=\"trade-after-content\" id=\"trade-3565963867\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>The Indian pharmaceutical industry is expected to double in value by 2030, presenting an attractive opportunity for long-term investment. Pharmaceutical stocks are appealing due to the sector&#8217;s resilience against market fluctuations and robust growth potential, fueled by rising healthcare demands and government support for innovation. Investors may find significant prospects in this evolving market landscape.&nbsp; [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":111747,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[22755,19821,9056,9055,948,936,3157,22756,11084],"class_list":["post-134117","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news","tag-fundamentally-strong-pharma-stocks-to-buy","tag-mankind-pharma","tag-mankind-pharma-latest-news","tag-mankind-pharma-share-price","tag-stock-market","tag-stock-market-news","tag-stock-to-watch","tag-yatharth-hospital","tag-yatharth-hospital-share-price"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Fundamentally strong pharma stocks to buy now for an upside of 30% - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"The Indian pharmaceutical industry is expected to double in value by 2030, presenting an attractive opportunity for long-term investment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fundamentally strong pharma stocks to buy now for an upside of 30%\" \/>\n<meta property=\"og:description\" content=\"The Indian pharmaceutical industry is expected to double in value by 2030, presenting an attractive opportunity for long-term investment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-23T04:15:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T04:15:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/\",\"url\":\"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/\",\"name\":\"Fundamentally strong pharma stocks to buy now for an upside of 30% - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"datePublished\":\"2024-09-23T04:15:16+00:00\",\"dateModified\":\"2024-09-23T04:15:20+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"The Indian pharmaceutical industry is expected to double in value by 2030, presenting an attractive opportunity for long-term investment.\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fundamentally strong pharma stocks to buy now for an upside of 30%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fundamentally strong pharma stocks to buy now for an upside of 30% - Trade Brains Features","description":"The Indian pharmaceutical industry is expected to double in value by 2030, presenting an attractive opportunity for long-term investment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/","og_locale":"en_US","og_type":"article","og_title":"Fundamentally strong pharma stocks to buy now for an upside of 30%","og_description":"The Indian pharmaceutical industry is expected to double in value by 2030, presenting an attractive opportunity for long-term investment.","og_url":"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2024-09-23T04:15:16+00:00","article_modified_time":"2024-09-23T04:15:20+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/","url":"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/","name":"Fundamentally strong pharma stocks to buy now for an upside of 30% - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","datePublished":"2024-09-23T04:15:16+00:00","dateModified":"2024-09-23T04:15:20+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"The Indian pharmaceutical industry is expected to double in value by 2030, presenting an attractive opportunity for long-term investment.","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/fundamentally-strong-pharma-stocks-to-buy-now-for-an-upside-of-30\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Fundamentally strong pharma stocks to buy now for an upside of 30%"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/134117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=134117"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/134117\/revisions"}],"predecessor-version":[{"id":134119,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/134117\/revisions\/134119"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/111747"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=134117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=134117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=134117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}